ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
2025-02-07Yahoo Finance
CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neur Read more
